Azura Ophthalmics Ltd.

The Ohio State University

Charles Bosworth

Omer Rafaeli

Yair Alster

Marc Gleeson

Mark Richard Stewart

Jonathan Dunn

Ian Holmes

Hila Barash

Robert M Burk

Hila Epstein-Barash

Nicholas Chapman

Melissa D Bailey

Alexander James Nicholls

Described herein are compositions and methods for the treatment of contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE). Such compositions comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of such compositions to the inner surface of the eyelid provides therapeutic benefit to patients suffering from contact lens discomfort (CLD) and/or lid wiper epitheliopathy (LWE).

Compositions and methods for the treatment of contact lens discomfort

Disclosed herein are methods and apparatus for making a determination about a cataract in an eye in ambient lighting conditions.

Methods and apparatus for detecting a presence and severity of a cataract in ambient lighting

Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/infections disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugate which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eye, ocular surface or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Compounds and methods for the treatment of ocular disorders

Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious disease of the anterior surface of the eye. Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Provided herein are methods treating a disease or disorder in or around the eye with a pharmaceutical composition comprising selenium disulfide (SeS) and instructing the treated individual to limit or avoid exposure to light following administration in order to reduce the adverse effect of the composition.

Instructions for composition and sensitivity

Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti-inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

Growing community of inventors

Las Vegas, NV, United States of America

Charles Bosworth